Why the study?
Hs-cTnI and T may perform differently for cardiovascular event prediction, and hs-cTnT can lose cardiovascular specificity in adults with myopathies and advanced age.
Does hs-cTnI perform differently than hs-cTnT for predicting cardiovascular outcomes in ambulatory adults?
Does hs-cTnI perform differently than hs-cTnT for predicting cardiovascular outcomes in ambulatory adults?
High-sensitivity cardiac troponin I and T perform similarly for predicting multiple cardiovascular endpoints in ambulatory adults, irrespective of age and pre-existing cardiovascular disease.
Answers are grounded in this paper and cite their sources.
hs-cTnI and hs-cTnT can be used interchangeably for CV risk stratification in ambulatory adults; confirms equivalent prognostic value across HF, MI, and CV death.
BACKGROUND: Cardiac troponin I and T measured by high-sensitivity assays (hs-cTn) are detectable in most ambulatory adults. Hs-cTnI and T may perform differently for prediction of cardiovascular (CV) events. In adults with myopathies and advanced age, hs-cTnT can lose CV specificity. We undertook a meta-analysis of ambulatory studies measuring hs-cTn to determine whether hs-cTnI is a superior predictor of CV outcomes. METHODS: Articles evaluating hs-cTnI or T for incident heart failure (HF), myocardial infarction (MI), CV, and all-cause death in ambulatory adults were screened. Adjusted HRs were extracted standardized as hs-cTn tertile 3 vs 1. Pooled effects were calculated, and heterogeneity assessed. Predefined subgroup analyses for hs-cTnI vs T included age and prevalent CV disease. RESULTS: A total of 5499 studies were screened and 54 met inclusion criteria with up to 277 498 participants followed for 8.1 ± 4.5 years. Pooled estimates for HF, MI, CV, and all-cause death were reported as 2.30 [95% confidence interval (CI) 2.04, 2.60], 1.64 (95%CI 1.47, 1.86), 2.07 (95%CI 1.82, 2.35), and 1.66 (95%CI 1.51, 1.83). No differences in HRs for subgroups based on hs-cTnI vs hs-cTnT (except all-cause death), age, or prevalent CV disease were observed. Heterogeneity between studies was high with an I2 > 60% for all endpoints for both hs-cTn assays. In a sensitivity analysis of studies measuring both hs-cTnI and T there was also no differences for the prediction of any CV endpoint. CONCLUSIONS: Hs-cTnI and T prediction of multiple CV endpoints are not significantly different irrespective of age and pre-existing CV disease in ambulatory adults.
No takes yet. Share an insight, caveat, or question.
Parashar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: